Skip to main content

Table 1 Comparison between included cases of leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) regarding clinicopathological features

From: The values of Transgelin, Stathmin, BCOR and Cyclin-D1 expression in differentiation between Uterine Leiomyosarcoma (ULMS) and Endometrial Stromal Sarcoma (ESS); diagnostic and prognostic implications

CharacteristicsAll (N = 44)LMS (N = 22)ESS (N = 22)
No. (%)No. (%)No. (%)
Age (years)
 Mean ± SD56.84 ±7.9362.50 ±4.9451.18 ±6.10
 Median (Range)57 (39-72)62 (56-72)50 (39-65)
 ≤ 55 years18 (40.9%)0 (0%)18 (81.8%)
 > 55 years26 (59.1%)22 (100%)4 (18.2%)
Size
 <5 cm6 (13.6%)4 (18.2%)2 (9.1%)
 >5 cm38 (86.4%)18 (81.8%)20 (90.9%)
Grade
 Grade I9 (20.5%)5 (22.7%)4 (18.2%)
 Grade II12 (27.3%)7 (31.8%)5 (22.7%)
 Grade III23 (52.3%)10 (45.5%)13 (59.1%)
Extrauterine extension
 Absent6 (13.6%)4 (18.2%)2 (9.1%)
 Present9 (20.5%)5 (22.7%)4 (18.2%)
 N/A29 (65.9%)13 (59.1%)16 (72.7%)
LVSI
 Absent21 (47.7%)14 (63.6%)7 (31.8%)
 Present23 (52.3%)8 (36.4%)15 (68.2%)
Bladder/Rectum extension
 Absent33 (75%)18 (81.8%)15 (68.2%)
 Present10 (22.7%)4 (18.2%)6 (27.3%)
 N/A1 (2.3%)0 (0%)1 (4.5%)
Other pelvic organ invasion
 Absent15 (34.1%)8 (36.4%)7 (31.8%)
 Present29 (65.9%)14 (63.6%)15 (68.2%)
Adnexal invasion
 Absent11 (25%)7 (31.8%)4 (18.2%)
 Present33 (75%)15 (68.2%)18 (81.8%)
Lymph node
 Negative16 (36.4%)10 (45.5%)6 (27.3%)
 Positive28 (63.6%)12 (54.5%)16 (72.7%)
Distant metastasis
 Absent29 (65.9%)18 (81.8%)11 (50%)
 Present15 (34.1%)4 (18.2%)11 (50%)